Lupin has received final approval for its levonorgestrel and ethinyl estradiol tablets USP, 0.1 mg / 0.02 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of Watson Laboratories Lutera 28 tablets.
Lupin’s levonorgestrel and ethinyl estradiol tablets are a combined oral contraceptive indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Lupin will be marketing its generic product shortly.
Lutera tablets had annual US sales of approximately $103.6 million.
EP News Bureau – Mumbai
